<!doctype html><html class=no-js lang=en><head><meta charset=UTF-8><meta name=viewport content="width=device-width,initial-scale=1"><title>ç§‘ç ”æ—¥æŠ¥ 2026-02-26 - ç”Ÿä¿¡æ™®æ‹‰æ–¯</title>
<script>(function(e,t){e[t]=e[t].replace("no-js","js")})(document.documentElement,"className")</script><meta name=description content><meta property="og:url" content="https://ixxmu.github.io/posts/dailyreports/2026-02-26/"><meta property="og:site_name" content="ç”Ÿä¿¡æ™®æ‹‰æ–¯"><meta property="og:title" content="ç§‘ç ”æ—¥æŠ¥ 2026-02-26"><meta property="og:description" content="ğŸ“… Daily Report - 2026-02-26 ä»Šæ—¥ç­›é€‰å‡º 53 æ¡å†…å®¹ï¼Œæ¥è‡ª 2 ä¸ªæ¥æº"><meta property="og:locale" content="zh_cn"><meta property="og:type" content="article"><meta property="article:section" content="posts"><meta property="article:published_time" content="2026-02-26T00:00:00+00:00"><meta property="article:modified_time" content="2026-02-26T00:00:00+00:00"><meta property="article:tag" content="Research"><meta property="article:tag" content="Daily"><meta property="article:tag" content="Week092026"><meta itemprop=name content="ç§‘ç ”æ—¥æŠ¥ 2026-02-26"><meta itemprop=description content="ğŸ“… Daily Report - 2026-02-26 ä»Šæ—¥ç­›é€‰å‡º 53 æ¡å†…å®¹ï¼Œæ¥è‡ª 2 ä¸ªæ¥æº"><meta itemprop=datePublished content="2026-02-26T00:00:00+00:00"><meta itemprop=dateModified content="2026-02-26T00:00:00+00:00"><meta itemprop=wordCount content="2615"><meta itemprop=keywords content="Research,Daily,Week092026"><meta name=twitter:card content="summary"><meta name=twitter:title content="ç§‘ç ”æ—¥æŠ¥ 2026-02-26"><meta name=twitter:description content="ğŸ“… Daily Report - 2026-02-26 ä»Šæ—¥ç­›é€‰å‡º 53 æ¡å†…å®¹ï¼Œæ¥è‡ª 2 ä¸ªæ¥æº"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=dns-prefetch href=//fonts.googleapis.com><link rel=dns-prefetch href=//fonts.gstatic.com><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,700"><link rel=stylesheet href=../../../css/style.css><link rel=stylesheet href=../../../css/custom.css><link rel="shortcut icon" href=../../../favicon.ico></head><body class=body><div class="container container--outer"><header class=header><div class="container header__container"><div class=logo><a class=logo__link href=../../../ title=ç”Ÿä¿¡æ™®æ‹‰æ–¯ rel=home><div class="logo__item logo__text"><div class=logo__title>ç”Ÿä¿¡æ™®æ‹‰æ–¯</div><div class=logo__tagline>è¿‘åå¹´æœ€å€¼å¾—ä¸Šæ‰‹çš„ç”Ÿç‰©åŒ»å­¦ç”Ÿä¿¡ä»£ç </div></div></a></div><nav class=menu><button class=menu__btn aria-haspopup=true aria-expanded=false tabindex=0>
<span class=menu__btn-title tabindex=-1>Menu</span></button><ul class=menu__list><li class=menu__item><a class=menu__link href=../../../posts/><span class=menu__text>æ–‡ç« </span></a></li><li class=menu__item><a class=menu__link href=../../../tags/><span class=menu__text>æ ‡ç­¾</span></a></li><li class=menu__item><a class=menu__link href=../../../about/><span class=menu__text>å…³äº</span></a></li></ul></nav></div></header><div class="wrapper flex"><div class=primary><main class=main role=main><article class=post><header class=post__header><meta name=referrer content="never"><h1 class=post__title>ç§‘ç ”æ—¥æŠ¥ 2026-02-26</h1><div class="post__meta meta"><div class="meta__item-datetime meta__item"><svg class="meta__icon icon icon-time" width="16" height="14" viewBox="0 0 30 28"><path d="M15 0a14 14 0 110 28 1 1 0 010-28m0 3a3 3 0 100 22 3 3 0 000-22m1 4h-2v8.4l6.8 4.4L22 18l-6-3.8z"/></svg><time class=meta__text datetime=2026-02-26T00:00:00Z>2026-02-26</time></div><div class="meta__item-categories meta__item"><svg class="meta__icon icon icon-category" width="16" height="16" viewBox="0 0 16 16"><path d="m7 2 1 2h8v11H0V2z"/></svg><span class=meta__text><a class=meta__link href=../../../categories/dailyreport/ rel=category>DailyReport</a></span></div><div class="meta__item-author meta__item"><svg class="meta__icon icon icon-author" width="16" height="16" viewBox="0 0 16 16"><path d="M8 1c2 0 3.5 2 3.5 4.5S10 9 10 9c3 1 4 2 4 6H2c0-4 1-5 4-6 0 0-1.5-1-1.5-3.5S6 1 8 1"/></svg><span class=meta__text>Bloger</span></div></div></header><div class="post__toc toc"><div class=toc__title>Page content</div><div class=toc__menu><nav id=TableOfContents><ul><li><a href=#-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</a><ul><li><a href=#-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</a></li><li><a href=#-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</a></li></ul></li><li><a href=#-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</a><ul><li></li></ul></li><li><a href=#-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</a></li><li><a href=#-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</a></li></ul></nav></div></div><div class="content post__content clearfix"><h1 id=-daily-report---2026-02-26>ğŸ“… Daily Report - 2026-02-26</h1><blockquote><p>ä»Šæ—¥ç­›é€‰å‡º <strong>53</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p></blockquote><div class=powered-by-top>Powered by <a href=https://kyplus.de>ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href=https://claude.ai>Claude</a></div><hr><h2 id=-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2><h3 id=-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
FGFRæŠ‘åˆ¶å‰‚åœ¨PIK3CAé©±åŠ¨çš„å­å®«å†…è†œç™Œä¸­å…‹æœæ²»ç–—è€è¯æ€§å’Œå…ç–«é€ƒé€¸ï¼Œä»¥åŠç”Ÿé…®é¥®é£Ÿè”åˆç–—æ³•å¢å¼ºFLT3-ITDæ€¥æ€§é«“ç³»ç™½è¡€ç—…æ²»ç–—æ•ˆæœã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>è‚¿ç˜¤ä»£è°¢è°ƒæ§ä¸ç™Œç—‡æ²»ç–—ï¼šç ”ç©¶ç”Ÿé…®é¥®é£Ÿå¯¹æ€¥æ€§é«“ç³»ç™½è¡€ç—…çš„ä½œç”¨ï¼Œä»¥åŠæ°®ä»£è°¢é€šè·¯åœ¨ç»†èƒçŠ¶æ€ä¸­çš„ä½œç”¨ã€‚</li><li>ä¿¡å·é€šè·¯ä¸ç™Œç—‡è¿›å±•ï¼šæ¢ç´¢FGFRæŠ‘åˆ¶å‰‚åœ¨å­å®«å†…è†œç™Œä¸­çš„ç–—æ•ˆï¼Œä»¥åŠåŸºå› ç»„é‡æ’å¯¹ä¹³è…ºç™Œè¿›å±•çš„å½±å“ã€‚</li><li>å…ç–«ç»†èƒåŠŸèƒ½ä¸è°ƒæ§ï¼šç ”ç©¶DOT1Lå¯¹æ ‘çªçŠ¶ç»†èƒäºšç¾¤å‘è‚²çš„å½±å“ï¼Œä»¥åŠciliatedç»†èƒé€šè¿‡STINGä»‹å¯¼çš„å…ç–«ç‹¬ç«‹æœºåˆ¶æŠ‘åˆ¶è‚¿ç˜¤å‘ç”Ÿã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>ç»“åˆé«˜é€šé‡æµ‹åºï¼ˆRNA-Seq, ChIP-Seq, ATAC-Seq, scRNA-Seqï¼‰ä¸ç”Ÿç‰©ä¿¡æ¯å­¦åˆ†æï¼Œæ·±å…¥è§£æåŸºå› ç»„ã€è½¬å½•ç»„åŠè¡¨è§‚é—ä¼ å­¦å˜åŒ–ã€‚</li><li>æ„å»ºäº†é¦–ä¸ªä¸´åºŠç›¸å…³çš„ã€å…ç–«æ´»æ€§çš„PIK3CAé©±åŠ¨çš„å­å®«å†…è†œç™Œå°é¼ æ¨¡å‹ã€‚</li></ul><h3 id=-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
ç ”ç©¶å‘ç°ï¼Œé˜¿å°”èŒ¨æµ·é»˜ç—…å¯èƒ½å§‹äºå¤§è„‘è¡€æµçš„æ—©æœŸã€æ— å£°ä¸‹é™ï¼Œè¿™ä¸€å˜åŒ–ä¸æ·€ç²‰æ ·è›‹ç™½æ–‘å—å’Œæµ·é©¬ä½“èç¼©ç­‰ç–¾ç—…æ ‡å¿—ç‰©å¯†åˆ‡ç›¸å…³ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>æ¢ç´¢å¤§è„‘è¡€æµå’Œæ°§æ°”æ¶ˆè€—çš„æ—©æœŸæ”¹å˜ä½œä¸ºé˜¿å°”èŒ¨æµ·é»˜ç—…è¯Šæ–­çš„æ½œåœ¨æŒ‡æ ‡ã€‚</li><li>å…³è”å¤§è„‘è¡€æµå˜åŒ–ä¸æ·€ç²‰æ ·è›‹ç™½æ²‰ç§¯åŠè®°å¿†åŠŸèƒ½å—æŸä¹‹é—´çš„æœºåˆ¶ã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>æå‡ºåˆ©ç”¨ç®€å•ã€æ— åˆ›æ€§æ‰«ææŠ€æœ¯è¿›è¡Œæ—©æœŸæ£€æµ‹çš„å¯èƒ½æ€§ã€‚</li></ul><hr><h2 id=-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</h2><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§¬ æ•°æ®å‰æ²¿ (52æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å‰10æ¡>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4><p><strong>1.</strong> â­ <strong>GSE319824 ç”Ÿé…®é¥®é£Ÿé¶å‘è°ƒèŠ‚å…¨èº«å’Œè‚¿ç˜¤ä»£è°¢å¹³è¡¡å¯å¢å¼ºFLT3-ITDæ€¥æ€§é«“ç³»ç™½è¡€ç—…çš„æ²»ç–—æ•ˆæœ</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€leukemiaã€metabolic</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jean-Emmanuel Sarry ; Fanny Granat ; LÃ©a Goupille ; Ambrine Sahal ; Tony KaomaSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensFMS-like tyrosine kinase 3 (FLT3) mutations in acute myeloid leukemia (AML) are associated with adverse prognosis. FLT3 inhibitors (FLT3i) improve therapeutic response, however diverse resistance mechanisms such as adaptations in lipid metabolism have been identified. We hypothesized that a lipid-rich ketogenic diet (KD) might alter both host and tumoral lipid metabolism, enhancing responses to FLT3i. In FLT3-mutated AML mouse models, three weeks of lard- or plant-based KD improved efficacy of FLT3i by two-fold reduction of engraftment and tumor burden. KD increased ketone bodies and lipid accumulation in plasma, liver and AML cells, and also induced a PUFA:MUFA imbalance. KD impacted pentoses, hexoses and amino acid metabolism, enhancing sugar phosphates and vitamins in host. Mechanistically, KD rewired anabolism towards fatty acid oxidation and glycine-utilizing pathways, modulated the expression of FLT3 signaling pathways and lipid biosynthesis, and promoted tumor cell differentiation. In conclusion, this study shows that KD reduces FLT3i-resistance, offering a promising therapeutic solution.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319824">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> â­ <strong>GSE311373 FGFRæŠ‘åˆ¶å‰‚å…‹æœè‡´ç™Œæ€§PIK3CAé©±åŠ¨çš„æµ†æ¶²æ€§å­å®«å†…è†œç™Œçš„æ²»ç–—è€è¯æ€§å’Œå…ç–«é€ƒé€¸</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€regex:onco(logy|logist|gene|genic)ã€resistance</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Xin ChengSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Mus musculusWe developed the first clinically relevant, immunocompetent SEC mouse model incorporating PIK3CA mutation, TP53 loss, and MYC overexpression. Through comprehensive analysis integrating mouse models, human cell lines, xenografts, and clinical samples, we investigated mechanisms of PIK3CA-targeted therapy resistance. Single-cell transcriptional profiling identified FGFR1/2 association with intrinsic resistance and FGFR3 with acquired resistance. Dual inhibition of FGFR and PI3Ka achieved enhanced tumor suppression. Additionally, we discovered that FGFR signaling promotes immune evasion by downregulating MHC-I/HLA-mediated antigen processing and presentation. Importantly, FGFR inhibition not only reversed immune suppression by restoring antigen presentation but also demonstrated a synergistic effect with anti-PD-1 therapy, enhancing immunotherapy response and anti-tumor immune memory. Our findings reveal FGFR&rsquo;s dual role in therapy resistance and immune evasion, supporting FGFR inhibition as a promising strategy to enhance treatment outcome in SEC patients.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311373">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> â­ <strong>GSE301939 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ DOT1L å½±å“æ ‘çªçŠ¶ç»†èƒäºšç¾¤çš„å‘è‚² [ChIP-Seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šdendritic cellã€ChIP-seqã€histone</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Willem-Jan de Leeuw ; Anne Mensink ; Rianne G Bouma ; Fred van Leeuwen ; Joke M den HaanSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusDendritic cells (DCs) are important orchestrators of immune responses and can be divided into two conventional DC subsets, cDC1s and cDC2s, and a plasmacytoid DC (pDC) subset, which are involved in the activation of T cells and production of type I interferons (IFNs), respectively. The development of the DC subsets occurs in the bone marrow (BM) under control of different transcription factors and epigenetic modifiers. The histone methyltransferase DOT1L, known as a druggable target in cancer, is emerging as a key epigenetic regulator of differentiation in lymphocytes. DOT1L writes methylation of lysine 79 of histone H3 in gene bodies of actively transcribed genes. Deletion or inhibition of DOT1L affects the differentiation trajectory of innate and adaptive immune cells, leading to altered cell states. Recent studies suggest that DOT1L also plays a role in DC function. Here, we investigated the role of DOT1L in the development of DCs in in vitro BM cultures and in vivo using a tamoxifen-inducible mouse model. H3K79me2 ChIPseq data of sorted DC subsets from the BM revealed distinct H3K79me2 peaks for all three subsets, which suggested differential regulation of the subsets by DOT1L. A comparison of the H3K79me2 ChIPseq data to bulk RNAseq of sorted DC subsets from the BM revealed a stronger correlation between H3K79me2 and global transcription in pDCs and cDC2s compared to cDC1s. In line with this, we observed that Dot1l deletion led to a decrease in pDCs and CpG A-stimulated IFNÎ± production and an increase in cDC2s in in vitro BM cultures, while cDC1s were unchanged. In vivo deletion of Dot1l led to a decrease in common myeloid progenitors (CMPs), monocyte DC progenitors (MDPs), and common DC progenitors (CDPs) in the BM, while common lymphoid progenitor (CLP) and cDC2 numbers were increased. Inhibition of DOT1L resulted in a similar phenotype, which linked the observed effects to the methyltransferase activity of DOT1L. Interestingly, all Dot1l-KO DC subsets exhibited an enrichment of pathways related to antigen presentation and the immune response and MHCII expression was upregulated in Dot1l-KO pDCs and cDC2s in vivo. To conclude, our data indicate that DOT1L function differentially affects the development of DCs with predominant effects in pDCs and cDC&mldr;</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301939">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> â­ <strong>GSE301937 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ DOT1L å½±å“æ ‘çªçŠ¶ç»†èƒäºšç¾¤çš„å‘è‚² [RNA-Seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šdendritic cellã€RNA-seqã€histone</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Willem-Jan de Leeuw ; Anne Mensink ; Rianne G Bouma ; Fred van Leeuwen ; Joke M den HaanSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusDendritic cells (DCs) are important orchestrators of immune responses and can be divided into two conventional DC subsets, cDC1s and cDC2s, and a plasmacytoid DC (pDC) subset, which are involved in the activation of T cells and production of type I interferons (IFNs), respectively. The development of the DC subsets occurs in the bone marrow (BM) under control of different transcription factors and epigenetic modifiers. The histone methyltransferase DOT1L, known as a druggable target in cancer, is emerging as a key epigenetic regulator of differentiation in lymphocytes. DOT1L writes methylation of lysine 79 of histone H3 in gene bodies of actively transcribed genes. Deletion or inhibition of DOT1L affects the differentiation trajectory of innate and adaptive immune cells, leading to altered cell states. Recent studies suggest that DOT1L also plays a role in DC function. Here, we investigated the role of DOT1L in the development of DCs in in vitro BM cultures and in vivo using a tamoxifen-inducible mouse model. H3K79me2 ChIPseq data of sorted DC subsets from the BM revealed distinct H3K79me2 peaks for all three subsets, which suggested differential regulation of the subsets by DOT1L. A comparison of the H3K79me2 ChIPseq data to bulk RNAseq of sorted DC subsets from the BM revealed a stronger correlation between H3K79me2 and global transcription in pDCs and cDC2s compared to cDC1s. In line with this, we observed that Dot1l deletion led to a decrease in pDCs and CpG A-stimulated IFNÎ± production and an increase in cDC2s in in vitro BM cultures, while cDC1s were unchanged. In vivo deletion of Dot1l led to a decrease in common myeloid progenitors (CMPs), monocyte DC progenitors (MDPs), and common DC progenitors (CDPs) in the BM, while common lymphoid progenitor (CLP) and cDC2 numbers were increased. Inhibition of DOT1L resulted in a similar phenotype, which linked the observed effects to the methyltransferase activity of DOT1L. Interestingly, all Dot1l-KO DC subsets exhibited an enrichment of pathways related to antigen presentation and the immune response and MHCII expression was upregulated in Dot1l-KO pDCs and cDC2s in vivo. To conclude, our data indicate that DOT1L function differentially affects the development of DCs with predominant effects in pDCs and cDC2s.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301937">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>5.</strong> â­ <strong>GSE292814 FGFRæŠ‘åˆ¶å‰‚å…‹æœè‡´ç™Œæ€§PIK3CAé©±åŠ¨çš„æµ†æ¶²æ€§å­å®«å†…è†œç™Œçš„æ²»ç–—è€è¯æ€§å’Œå…ç–«é€ƒé€¸</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€regex:onco(logy|logist|gene|genic)ã€resistance</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Xin ChengSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusWe developed the first clinically relevant, immunocompetent SEC mouse model incorporating PIK3CA mutation, TP53 loss, and MYC overexpression. Through comprehensive analysis integrating mouse models, human cell lines, xenografts, and clinical samples, we investigated mechanisms of PIK3CA-targeted therapy resistance. Single-cell transcriptional profiling identified FGFR1/2 association with intrinsic resistance and FGFR3 with acquired resistance. Dual inhibition of FGFR and PI3Ka achieved enhanced tumor suppression. Additionally, we discovered that FGFR signaling promotes immune evasion by downregulating MHC-I/HLA-mediated antigen processing and presentation. Importantly, FGFR inhibition not only reversed immune suppression by restoring antigen presentation but also demonstrated a synergistic effect with anti-PD-1 therapy, enhancing immunotherapy response and anti-tumor immune memory. Our findings reveal FGFR&rsquo;s dual role in therapy resistance and immune evasion, supporting FGFR inhibition as a promising strategy to enhance treatment outcome in SEC patients.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292814">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>6.</strong> â­ <strong>GSE320216 ä¹³è…ºç™Œè¿›å±•è¿‡ç¨‹ä¸­åŸºå› ç»„é‡ç»„åŠå…¶åŠŸèƒ½å½±å“ [RNA-Seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€genome</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Kathleen S Reed ; Tom Misteli ; Andrew Fritz ; Haley Greenyer ; Seth Frietze ; Janet Stein ; Gary SteinSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTo explore how chromatin structure and epigenetic parameters of genome architecture changes during cancer progression at a fine scale and genome-wide, we generated high-resolution Micro-C contact maps in non-malignant, pre-cancerous, and metastatic MCF10 breast cancer epithelial cells. We profiled progression-associated reorganization of chromatin compartments, topologically associated domains (TADs), and chromatin loops, and also identified invariable chromatin features. We find large-scale compartmental shifts occur predominantly in early stages of cancer development, with more fine-scale structural changes in TADs and looping accumulating during the later transition to metastasis. We related these structural features to changes in gene expression, histone marks, and potential enhancers and found a large portion of differentially expressed genes physically connected to distal regulatory elements. While changes in chromatin loops were relatively rare during progression, differential loops were enriched for progression-associated genes, including those involved in proliferation, angiogenesis, and differentiation. Changes in either enhancer-promoter contacts or distal enhancer activity were accompanied by differential gene regulation, suggesting that changes in chromatin contacts are not necessary but can be sufficient for gene regulation. Together, our results demonstrate a functionally relevant connection between gene regulation and genome remodeling at many key genes during cancer progression.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320216">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>7.</strong> â­ <strong>GSE320215 ä¹³è…ºç™Œè¿›å±•è¿‡ç¨‹ä¸­åŸºå› ç»„é‡ç»„åŠå…¶åŠŸèƒ½å½±å“ [ATAC-Seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ATAC-seqã€genome</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Kathleen S Reed ; Tom Misteli ; Andrew Fritz ; Haley Greenyer ; Seth Frietze ; Janet Stein ; Gary SteinSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensTo explore how chromatin structure and epigenetic parameters of genome architecture changes during cancer progression at a fine scale and genome-wide, we generated high-resolution Micro-C contact maps in non-malignant, pre-cancerous, and metastatic MCF10 breast cancer epithelial cells. We profiled progression-associated reorganization of chromatin compartments, topologically associated domains (TADs), and chromatin loops, and also identified invariable chromatin features. We find large-scale compartmental shifts occur predominantly in early stages of cancer development, with more fine-scale structural changes in TADs and looping accumulating during the later transition to metastasis. We related these structural features to changes in gene expression, histone marks, and potential enhancers and found a large portion of differentially expressed genes physically connected to distal regulatory elements. While changes in chromatin loops were relatively rare during progression, differential loops were enriched for progression-associated genes, including those involved in proliferation, angiogenesis, and differentiation. Changes in either enhancer-promoter contacts or distal enhancer activity were accompanied by differential gene regulation, suggesting that changes in chromatin contacts are not necessary but can be sufficient for gene regulation. Together, our results demonstrate a functionally relevant connection between gene regulation and genome remodeling at many key genes during cancer progression.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320215">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>8.</strong> <strong>GSE315728 MS æ‚£è€…è‚ é“ä¸­å›è‚ ä¸Šçš®å’Œå…ç–«ç»†èƒè°±çš„æ”¹å˜ã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€regex:intestin(e|al)</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Shohei Suzuki ; Kentaro Miyamoto ; Jonathan Moody ; Tomohisa SujinoSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe intestinal epithelium plays a critical role in immuneâ€“microbiota interactions, yet its contribution to systemic autoimmunity remains unclear. Here, we identify intestinal epithelial cells (IECs) as key initiators of experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis (MS). In MS patients, IECs upregulate antigen presentationâ€“related genes and associate with increased intestinal Th17 cell accumulation.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315728">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>9.</strong> <strong>GSE320388 æ°®ä»£è°¢è°±åˆ†ææ­ç¤ºç»†èƒçŠ¶æ€ç‰¹å¼‚æ€§å˜§å•¶åˆæˆé€”å¾„é€‰æ‹©</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmetabolismã€pathway</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Milan R Savani ; Bingbing Li ; Tracey Shipman ; Samuel K McBrayerSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensStable isotope tracing assays track few metabolites, yet cells use many nutrients to sustain nitrogen metabolism. Here, we create a platform for tracing 30 nitrogen isotope-labeled metabolites in parallel to enable a system-level understanding of cellular nitrogen metabolism. This platform reveals that while primitive cells engage both de novo and salvage pyrimidine synthesis pathways, differentiated cells nearly exclusively salvage uridine. This link between cell state and pyrimidine synthesis pathway preference persists in murine and human tissues. Mechanistically, we find that S1900 phosphorylation of CAD, the first enzyme of the de novo pathway, is induced by uridine deprivation in differentiated cells and constitutively enriched in primitive cells. Mimicking CAD S1900 phosphorylation in differentiated cells constitutively activates de novo pyrimidine synthesis, while blocking this modification impairs the cellular response to uridine starvation. Collectively, we establish a method for nitrogen metabolism profiling and define a mechanism of cell state-specific pyrimidine synthesis pathway choice.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320388">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>10.</strong> <strong>GSE308878 çº¤æ¯›ç»†èƒé€šè¿‡STINGä»‹å¯¼çš„è‚¿ç˜¤æŠ‘åˆ¶çš„å…ç–«éä¾èµ–æ€§æœºåˆ¶é˜»æ­¢è‚¿ç˜¤å‘ç”Ÿ</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immune</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jose A Colina ; Rong Wu ; Brian Magnuson ; Kathleen R Cho ; Analisa DiFeoSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusMitigating DNA damage in the fallopian tube epithelium (FTE) is essential for preventing tubo-ovarian high-grade serous carcinoma (HGSC). Here we demonstrate that Stimulator of Interferon Genes (STING) is abundantly expressed in the ciliated cells of the FTE and functions as a critical immune-independent tumor suppressor. Using patient samples, mouse models, and organoid systems, we demonstrate that ciliated cells mount a dual protective response to ovulation-associated genotoxic stress: intrinsic STING-driven apoptosis and extrinsic clearance of neighboring damaged secretory cells via TNFÎ± secretion. This surveillance mechanism markedly limits DNA damage accumulation within the epithelial microenvironment. Crucially, while these mechanisms are vital for maintaining homeostasis and reducing genomic instability, they fail to impact p53-deficient precursor lesions as both intrinsic and extrinsic pro-apoptotic processes rely on functional p53 signaling. These findings redefine ciliated cells as key guardians of genome integrity rather than passive bystanders and implicate early loss of STING-high ciliated cells as a pivotal event in HGSC initiation with potential relevance for prevention and therapeutic intervention.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308878">æŸ¥çœ‹åŸæ–‡</a></li></ul><blockquote><p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 42 æ¡å†…å®¹ï¼Œè¯¦è§ <a href=#%E6%9B%B4%E5%A4%9A-%E6%95%B0%E6%8D%AE%E5%89%8D%E6%B2%BF>æ–‡æœ«</a></p></blockquote></div></details><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§ª åšå®¢æ›´æ–° (1æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å…¨éƒ¨1æ¡>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4><p><strong>1.</strong> <strong>é˜¿å°”èŒ¨æµ·é»˜ç—…å¯èƒ½å§‹äºè„‘è¡€æµé‡çš„æ‚„ç„¶ä¸‹é™ã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSubtle changes in brain blood flow and oxygen use are closely linked to hallmark signs of Alzheimerâ€™s, including amyloid plaques and memory-related brain shrinkage. Simple, noninvasive scans may one day help spot risk earlierâ€”by looking at the brainâ€™s vascular health, not just its plaques.</li><li>ğŸ”— <a href=https://www.sciencedaily.com/releases/2026/02/260224023159.htm>æŸ¥çœ‹åŸæ–‡</a></li></ul></div></details><h2 id=-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2><table><thead><tr><th>å…³é”®è¯</th><th>å‡ºç°æ¬¡æ•°</th></tr></thead><tbody><tr><td>RNA-seq</td><td>10</td></tr><tr><td>immune</td><td>6</td></tr><tr><td>histone</td><td>6</td></tr><tr><td>cancer</td><td>6</td></tr><tr><td>genome</td><td>5</td></tr><tr><td>macrophage</td><td>5</td></tr><tr><td>tumor</td><td>4</td></tr><tr><td>metabolic</td><td>3</td></tr><tr><td>inflammation</td><td>3</td></tr><tr><td>scRNA</td><td>3</td></tr><tr><td>regex:intestin(e</td><td>al)</td></tr><tr><td>regex:onco(logy</td><td>logist</td></tr><tr><td>resistance</td><td>2</td></tr><tr><td>metabolism</td><td>2</td></tr><tr><td>dendritic cell</td><td>2</td></tr><tr><td>ChIP-seq</td><td>2</td></tr><tr><td>ATAC-seq</td><td>2</td></tr><tr><td>transcriptome</td><td>2</td></tr><tr><td>carcinoma</td><td>2</td></tr><tr><td>bioinformatics</td><td>1</td></tr></tbody></table><hr><h2 id=-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</h2><details><summary><a name=æ›´å¤š-æ•°æ®å‰æ²¿></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (42æ¡)</summary><div class=details-content markdown=1><ul><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300991">å¯¹ä»å°é¼ ä¹³è…ºè‚¿ç˜¤ä¸­åˆ†ç¦»çš„ CD45 é˜³æ€§ç»†èƒè¿›è¡Œäº† GSE300991 å•ç»†èƒ RNA æµ‹åºåˆ†æã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281293">GSE281293 KSHVè£‚è§£æ€§å†æ¿€æ´»åçš„å…¨åŸºå› ç»„è½¬å½•ç»„åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319658">GSE319658 é€‰æ‹©æ€§é¶å‘ç»„è›‹ç™½æ ·æ²‰é»˜å­ Sfx è‡³ R6K æ¥åˆè½¬ç§»æ“çºµå­ [ChIP-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319657">GSE319657 ç»„è›‹ç™½æ ·æ²‰é»˜å­ Sfx é€‰æ‹©æ€§é¶å‘ R6K æ¥åˆè½¬ç§»æ“çºµå­ [RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320319">GSE320319 åŸºå› ç»„é‡ç»„åŠå…¶åœ¨ä¹³è…ºç™Œè¿›å±•è¿‡ç¨‹ä¸­çš„åŠŸèƒ½å½±å“</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302079">GSE302079 è†€èƒ±ç™ŒåŸºå› å·¥ç¨‹å°é¼ æ¨¡å‹è¡ç”Ÿè‚¿ç˜¤ç»†èƒç³»çš„è¡¨å¾</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287674">GSE287674 MafB æ˜¯è·¨ç»„ç»‡å’Œç‰©ç§çš„å·¨å™¬ç»†èƒå‘è‚²å’Œèº«ä»½çš„ä¿å®ˆè½¬å½•è°ƒèŠ‚å› å­ [scRNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286897">GSE286897 MafB æ˜¯è·¨ç»„ç»‡å’Œç‰©ç§çš„å·¨å™¬ç»†èƒå‘è‚²å’Œèº«ä»½çš„ä¿å®ˆè½¬å½•è°ƒèŠ‚å› å­ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320312">GSE320312 æŠ—TIM3-IFNèåˆè›‹ç™½é€šè¿‡æ¿€æ´»è‚¿ç˜¤å†…æ ‘çªçŠ¶ç»†èƒï¼Œä½¿è‚¿ç˜¤æµ¸æ¶¦çš„è€—ç«­TIM3+CD8+Tç»†èƒæ¢å¤æ´»åŠ›</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320308">GSE320308 PD0325901 Alleviates Thrombin-Inhibited Osteogenic Differentiation Through an IL-1Î²-Activated Feedback Loop between MEK-Erk1/2 and NF-ÎºB Signal Pathways: Insights from Bioinformatics and Experimental Verification</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307339">GSE307339 ç‚ç—‡å¢å¼ºæˆå¹´APPå°èƒ¶è´¨ç»†èƒåœ¨å¾®æµæ§ç¥ç»å…ƒ-å°èƒ¶è´¨ç»†èƒå…±åŸ¹å…»æ¨¡å‹ä¸­çš„çªè§¦ç‰¹å¼‚æ€§åå™¬ä½œç”¨</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305554">GSE305554 m6A è¡¨è§‚è½¬å½•ç»„è°ƒæ§è§†ç½‘è†œç¥ç»èŠ‚ç»†èƒçš„è½´çªå‘ç”Ÿå’Œé‡ç¼–ç¨‹ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296812">GSE296812ï¼šç»„è›‹ç™½ä¿®é¥°æ—¶é’Ÿåœ¨è·¨ç‰©ç§ç”Ÿç‰©å¹´é¾„é¢„æµ‹ä¸­çš„ç¨³å¥åº”ç”¨åŠè¡°è€è°ƒæ§æœºåˆ¶çš„é˜æ˜</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE234721">GSE234721 æœè‡ piRNA ç°‡å¼‚æŸ“è‰²è´¨åœ¨æ€¥æ€§çƒ­ä¼‘å…‹åçš„å¿«é€Ÿè§£ä½“å’Œ Piwi éä¾èµ–æ€§é‡ç»„ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315447">GSE315447 22q11.2å¾®ç¼ºå¤±ä½ç‚¹ç¼–ç çš„å•å€ä½“ä¸è¶³çº¿ç²’ä½“åŸºå› ä¹‹é—´çš„æŠ‘åˆ¶æ€§é—ä¼ ç›¸äº’ä½œç”¨å†³å®šäº†å¤§è„‘å’Œå¿ƒè„è¡¨å‹</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307353">GSE307353 Siglec-F å¯ä¿æŠ¤å°é¼ å…å—å¼¹æ€§è›‹ç™½é…¶è¯±å¯¼çš„è‚ºéƒ¨ç‚ç—‡å’Œè‚ºæ°”è‚¿</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304577">GSE304577 æ…¢æ€§å¯å¡å› ä½¿ç”¨éšœç¢ä¸­å£è…”åˆ°è¡€æ¶²å¾®ç”Ÿç‰©DNAæ˜“ä½çš„ç‰¹å¾åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292232">GSE292232 å°é¼ åè‚¢éª¨éª¼è‚Œåœ¨èƒšèƒæœŸå’Œæˆå¹´æœŸæ…¢è‚Œçº¤ç»´å«é‡å·®å¼‚çš„åŸºå› ç»„ç‰¹å¾[RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292230">GSE292230 å°é¼ åè‚¢éª¨éª¼è‚Œåœ¨èƒšèƒæœŸå’Œæˆå¹´æœŸæ…¢è‚Œçº¤ç»´å«é‡å·®å¼‚çš„åŸºå› ç»„ç‰¹å¾ [ATAC-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281295">GSE281295 KSHVè£‚è§£æ€§å†æ¿€æ´»è¿‡ç¨‹ä¸­ç»†èƒmiRNAè½¬å½•ç»„çš„ç‰¹å¾åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315102">GSE315102 ç™½ç»†èƒä»‹ç´ -2-TGF-Î² æ›¿ä»£æ¿€åŠ¨å‰‚å¯è½»æ¾è¯±å¯¼å…ç–«è€å—</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314399">GSE314399 äººç±» Flower åŒå·¥å‹ hFWE4 ä¿ƒè¿›çš®è‚¤é³çŠ¶ç»†èƒç™Œçš„è§’åŒ–</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313932">GSE313932 FOXO1 æ•´åˆåŠ¨è„‰ç²¥æ ·ç¡¬åŒ–ä¸­çš„å†…çš®è¡€æµåŠ¨åŠ›å­¦ã€ç‚ç—‡å’Œä»£è°¢é€šè·¯ [LSS]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313931">GSE313931 FOXO1 æ•´åˆåŠ¨è„‰ç²¥æ ·ç¡¬åŒ–ä¸­çš„å†…çš®è¡€æµåŠ¨åŠ›å­¦ã€ç‚ç—‡å’Œä»£è°¢é€šè·¯ [OSS]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285051">GSE285051 äººç±»å¹²ç»†èƒè¡ç”Ÿç¾ä¸¸æ ·ç±»å™¨å®˜ä¸­å¤šç§ç¾ä¸¸ç»†èƒè°±ç³»çš„å‡ºç° [scRNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285050">GSE285050 äººç±»å¹²ç»†èƒè¡ç”Ÿç¾ä¸¸æ ·ç±»å™¨å®˜ä¸­å¤šç§ç¾ä¸¸ç»†èƒè°±ç³»çš„å‡ºç° [RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268687">GSE268687 nBAFå¤åˆç‰©äºšåŸºCREST/SS18L1é€šè¿‡é…ªæ°¨é…¸397å’Œç»„è›‹ç™½ä¹™é…°è½¬ç§»é…¶CBPè°ƒèŠ‚æµ·é©¬è®°å¿†è¿‡ç¨‹</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE243065">GSE243065 åŸºå› ç»„ç¼–è¾‘ä¸­æœ€å¤§é™åº¦å‡å°‘å¤§èŒƒå›´æŸ“è‰²è´¨æ‰°åŠ¨å¯ä¿æŠ¤å¹²ç»†èƒç‰¹æ€§</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320155">GSE320155 äººç±»è‚å†… CD4âº T ç»†èƒçš„å•ç»†èƒ RNA æµ‹åºç»“æœæ­ç¤ºäº†å¥åº·è‚è„å’Œè‚ç»†èƒç™Œ (HCC) è‚è„æ ·æœ¬ä¸­ç‹¬ç‰¹çš„ Treg è½¬å½•ç‰¹å¾å’Œä¸¤ç§ç¨³æ€ç»„ç»‡é€‚åº”ç¨‹åºã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320120">GSE320120 ç¡«ä»£é»„ç´ é€šè¿‡é‡å¡‘é…µæ¯è½¬å½•å’Œä»£è°¢å»¶é•¿å¤åˆ¶å¯¿å‘½</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303683">GSE303683 RNA-seq æ•°æ®æ¥è‡ª GBM æ‚£è€…å’Œé…å¯¹ç±»å™¨å®˜</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303409">GSE303409 é‰´å®šè‚ºç™Œæ”¾å°„æŠ—æ€§åŸºå›  [CRISPR ç­›é€‰]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303209">GSE303209 è‚ éšçªæ˜¯æˆŠå‹è‚ç‚ç—…æ¯’æ„ŸæŸ“çš„æ½œåœ¨å‚¨å­˜åº“</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299009">GSE299009 ä½å¼ºåº¦è¶…å£° (LIUS) è¯±å¯¼çš„éå°ç»†èƒè‚ºç™Œ (NSCLC) ç»†èƒç³»è½¬å½•ç»„æ”¹å˜ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295920">GSE295920 è†€èƒ±ç™Œçš„åŸºå› å·¥ç¨‹å°é¼ æ¨¡å‹å’ŒåŒåŸºå› ç§»æ¤æ¨¡å‹</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291409">GSE291409 BALF åŸºå› è¡¨è¾¾è°±åˆ†ææ­ç¤ºäº† COVID-19 åæŒç»­æ€§ ILD ä¸­å…ˆå¤©å…ç–«æ¿€æ´»çš„åå€š</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290421">GSE290421 äºŒåäºŒç¢³å…­çƒ¯é…¸é€šè¿‡å…¶æ°§è„‚è´¨ä¿æŠ¤è‚ºéƒ¨å…å—è‡­æ°§è¯±å¯¼çš„ç‚ç—‡ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290387">GSE290387 å¯¹ 1-5 å²å¹¼å„¿é¼»è…”åˆ®åŒ™æˆ–æ‹­å­æ ·æœ¬è¿›è¡Œ RNA æµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287476">GSE287476 MafB æ˜¯è·¨ç»„ç»‡å’Œç‰©ç§çš„å·¨å™¬ç»†èƒå‘è‚²å’Œèº«ä»½çš„ä¿å®ˆè½¬å½•è°ƒèŠ‚å› å­ [CUT&amp;RUN 2]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287347">GSE287347 MafB æ˜¯å·¨å™¬ç»†èƒå‘è‚²å’Œç‰¹æ€§åœ¨ä¸åŒç»„ç»‡å’Œç‰©ç§ä¸­ä¿å®ˆçš„è½¬å½•è°ƒæ§å› å­ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287346">GSE287346 MafB æ˜¯è·¨ç»„ç»‡å’Œç‰©ç§çš„å·¨å™¬ç»†èƒå‘è‚²å’Œèº«ä»½çš„ä¿å®ˆè½¬å½•è°ƒèŠ‚å› å­ [CUT&amp;Run]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272963">GSE272963 æ¶æ€§ç–ŸåŸâ€‹â€‹è™«ä¸´åºŠæ ·æœ¬ä¸­çº¿ç²’ä½“å¤©ç„¶åä¹‰è½¬å½•æœ¬çš„å·®å¼‚è¡¨è¾¾åœ¨å¤šç§ç–¾ç—…è¡¨å‹ä¸­çš„ç ”ç©¶</a></li></ul></div></details><hr><p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-02-25 21:53</em><br><em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p></div><footer class=post__footer><div class="post__tags tags clearfix"><svg class="tags__badge icon icon-tag" width="16" height="16" viewBox="0 0 32 32"><path d="M4 0h8s2 0 4 2l15 15s2 2 0 4L21 31s-2 2-4 0L2 16s-2-2-2-4V3s0-3 4-3m3 10a3 3 0 000-6 3 3 0 000 6"/></svg><ul class=tags__list><li class=tags__item><a class="tags__link btn" href=../../../tags/research/ rel=tag>Research</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/daily/ rel=tag>Daily</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/week092026/ rel=tag>Week092026</a></li></ul></div></footer></article></main><div class="authorbox clearfix"><div class=authorbox__header><span class=authorbox__name>About Bloger</span></div></div><nav class="pager flex"><div class="pager__item pager__item--prev"><a class=pager__link href=../../../posts/dailyreports/2026-02-25/ rel=prev><span class=pager__subtitle>Â«&#8201;Previous</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2026-02-25</p></a></div></nav><section class=comments><div id=disqus_thread></div><script>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//kkitown.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></section></div><aside class=sidebar><div class="widget-search widget"><form class=widget-search__form role=search method=get action=https://google.com/search><input class=widget-search__field type=search placeholder=Searchâ€¦ name=q aria-label=Searchâ€¦>
<input class=widget-search__submit type=submit value=Search>
<input type=hidden name=sitesearch value=https://ixxmu.github.io/></form></div><div class="widget-recent widget"><h4 class=widget__title>Recent Posts</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-26/>ç§‘ç ”æ—¥æŠ¥ 2026-02-26</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-25/>ç§‘ç ”æ—¥æŠ¥ 2026-02-25</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-24/>ç§‘ç ”æ—¥æŠ¥ 2026-02-24</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-23/>ç§‘ç ”æ—¥æŠ¥ 2026-02-23</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-22/>ç§‘ç ”æ—¥æŠ¥ 2026-02-22</a></li></ul></div></div><div class="widget-categories widget"><h4 class=widget__title>Categories</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../categories/dailyreport/>DailyReport</a></li><li class=widget__item><a class=widget__link href=../../../categories/learnr/>LearnR</a></li></ul></div></div><div class="widget-taglist widget"><h4 class=widget__title>Tags</h4><div class=widget__content><a class="widget-taglist__link widget__link btn" href=../../../tags/daily/ title=Daily>Daily (119)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/research/ title=Research>Research (119)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week022026/ title=Week022026>Week022026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week032026/ title=Week032026>Week032026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week042026/ title=Week042026>Week042026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week052026/ title=Week052026>Week052026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week062026/ title=Week062026>Week062026 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week072026/ title=Week072026>Week072026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week082026/ title=Week082026>Week082026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week452025/ title=Week452025>Week452025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week462025/ title=Week462025>Week462025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week472025/ title=Week472025>Week472025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week482025/ title=Week482025>Week482025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week492025/ title=Week492025>Week492025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week502025/ title=Week502025>Week502025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week512025/ title=Week512025>Week512025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week522025/ title=Week522025>Week522025 (7)</a></div><a href=../../../tags/></a></div><div class="widget-social widget"><h4 class="widget-social__title widget__title">Social</h4><div class="widget-social__content widget__content"><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Facebook rel="noopener noreferrer" href=https://facebook.com/username target=_blank><svg class="widget-social__link-icon icon icon-facebook" width="24" height="24" viewBox="0 0 352 352"><path d="m0 32v288c0 17.5 14.5 32 32 32h288c17.5.0 32-14.5 32-32V32c0-17.5-14.5-32-32-32H32C14.5.0.0 14.5.0 32zm320 0v288h-83V212h41.5l6-48H237v-31c0-14 3.5-23.5 23.5-23.5h26V66c-4.4-.6-19.8-1.5-37.5-1.5-36.9.0-62 22.2-62 63.5v36h-42v48h42v108H32V32z"/></svg>
<span>Facebook</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Twitter rel="noopener noreferrer" href=https://twitter.com/username target=_blank><svg class="widget-social__link-icon icon icon-twitter" width="24" height="24" viewBox="0 0 384 312"><path d="m384 36.9c-14.1 6.3-29.3 10.5-45.2 12.4 16.3-9.7 28.8-25.2 34.6-43.6-15.2 9-32.1 15.6-50 19.1-14.4-15.2-34.9-24.8-57.5-24.8-43.5.0-78.8 35.3-78.8 78.8.0 6.2.7 12.2 2 17.9-65.5-3.3-123.5-34.6-162.4-82.3C20 26 16.1 39.6 16.1 54c0 27.3 13.9 51.4 35 65.6-12.9-.4-25.1-4-35.7-9.9v1c0 38.2 27.2 70 63.2 77.2-6.6 1.8-13.6 2.8-20.8 2.8-5.1.0-10-.5-14.8-1.4 10 31.3 39.1 54.1 73.6 54.7-27 21.1-60.9 33.7-97.8 33.7-6.4.0-12.6-.4-18.8-1.1C34.9 299 76.3 312 120.8 312c144.9.0 224.1-120 224.1-224.1.0-3.4-.1-6.8-.2-10.2 15.4-11.1 28.7-25 39.3-40.8z"/></svg>
<span>Twitter</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Instagram rel="noopener noreferrer" href=https://www.instagram.com/username target=_blank><svg class="widget-social__link-icon icon icon-instagram" width="24" height="24" viewBox="0 0 256 256"><circle cx="193" cy="59" r="15"/><path fill-rule="evenodd" d="M101 0h54c41 0 58.4 3.9 74.5 17C256.2 37.5 256 74.8 256 97.7v60c0 26.7.0 60.4-26.5 81.4-16 13.4-33.5 16.9-74.5 16.9h-54c-41 0-57.5-3.5-74.5-16.9C1 218.9.5 186.3.1 160.5L0 155V97.7c0-23-.2-60.2 26.5-80.7C45 2 60 0 101 0zm4.9 23h44.3c45.8.0 58.3 3.5 70.3 17.5 11.8 13.2 12 30.1 12.5 62.9V156c.2 20.8.3 45.8-12.5 59.5-12 14-24.5 17.5-70.3 17.5h-44.3c-45.9.0-57.3-3.5-70.4-17.5-12.2-13-12.3-36.5-12.4-56.7v-55.6c.4-32.6.7-49.6 12.4-62.7C48 26.5 60 23 105.9 23zm19.6 144.5a42 42 0 100-84 42 42 0 000 84zm0 22.5a64.5 64.5.0 100-129 64.5 64.5.0 000 129z"/></svg>
<span>Instagram</span></a></div></div></div></aside></div><footer class=footer><div class="container footer__container flex"><div class=footer__copyright>&copy; 2026 ç”Ÿä¿¡æ™®æ‹‰æ–¯.
<span class=footer__copyright-credits>Generated with <a href=https://gohugo.io/ rel="nofollow noopener" target=_blank>Hugo</a> and <a href=https://github.com/Vimux/Mainroad/ rel="nofollow noopener" target=_blank>Mainroad</a> theme.</span></div></div></footer></div><script async defer src=../../../js/menu.js></script><script src=../../../js/custom.js></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.6/MathJax.js?config=TeX-AMS-MML_HTMLorMML" async></script></body></html>